Navigation Links
Panacea Pharmaceuticals Engages Accelovance For Clinical Development Of Its Novel Nanoparticle-Based Therapeutic Cancer Vaccine

GAITHERSBURG, Md., Feb. 10, 2015 /PRNewswire/ -- Panacea Pharmaceuticals, Inc. and Accelovance Inc. today announced the establishment of a clinical development services agreement to develop and advance Panacea's oncology immunotherapy pipeline. Through this agreement, Accelovance will support Panacea's clinical development strategies by offering scientific/medical and regulatory expertise, in addition to providing Contract Research Organization (CRO) support through Project Management, Clinical Monitoring, Data Management, Biostatistics, and Safety services for Panacea's clinical trials. The Panacea and Accelovance partnership will bring together highly complementary capabilities to advance and expedite Panacea's drug development and clinical advancement.   

Under the agreement, Panacea will maintain stringent oversight and quality standards relating to patient safety and regulatory compliance, with Accelovance assisting with the development and implementation of clinical strategies. Panacea will rely on Accelovance's knowledge in the areas of vaccines, oncology, and clinical management.  Providing advanced insight into Panacea's development pipeline will enable both organizations to enhance operational planning, consistency, and execution.  

"We are extremely excited to enter into this partnership, as Oncology immunotherapeutic development is vital for the future of patient treatment.  We are confident about our preclinical data in animal models and are ready for the next step in our company's development. With Accelovance we have found the best team to support our clinical development needs, which will continue to drive our oncology immunotherapy pipeline forward," commented Hossein Ghanbari, Ph.D., Panacea's Chief Executive Officer.

About Panacea

Panacea Pharmaceuticals, Inc. was founded in 1999 to discover, develop, and commercialize novel therapeutic and diagnostic products for oncology and diseases of the central nervous system. Since its inception, the Company's primary approach to cancer treatment has been immunotherapy and development of companion diagnostics for comprehensive patient management.  The Company's lead drug product candidate is a nanoparticle-based therapeutic cancer vaccine that targets a novel patented tumor marker, human aspartyl (asparaginyl) beta-hydroxylase (HAAH).  The company relies on a close collaboration with Brown University/Rhode Island Hospital in Providence, Rhode Island where teams of researchers are continuing advances on the Company's core technologies.  For more information, visit the company's Web site at

About Accelovance

Accelovance, Inc., headquartered in Rockville, MD, is an Industry award-winning Contract Research Organization (CRO) focused primarily in Oncology, Vaccines, and General Medicine. As a clinical services provider to the pharmaceutical and biotechnology industries, Accelovance offers comprehensive clinical development services including management and implementation of Phase I-IV clinical trials and a Clinical Call Center utilized for recruitment, post-marketing surveillance, and long-term survival follow-up. For more information, visit the company's Web site at  

Contact Information:

Steven Fuller, Ph.D., COO 

Hossein Ghanbari, Ph.D., CEO 

SOURCE Panacea Pharmaceuticals, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Panacea Pharmaceuticals Presents Three Papers Regarding Its Nanoparticle-Based Therapeutic Cancer Vaccine at the Society for Immunotherapy of Cancer Annual Meeting at National Harbor, MD
2. Anthera Pharmaceuticals Announces Completion of Interim Analysis from Phase 3 Trial with Blisibimod for Systemic Lupus Erythematosus
3. Spinifex Pharmaceuticals Enhances CMC Team With Two Senior Appointments
4. Lyophilisation for Pharmaceuticals: Products and Services 2015-2025 & Future Prospects for Leading Companies
5. Apellis Pharmaceuticals Enters Clinical Testing Phase in its Age-Related Macular Degeneration Program
6. Isis Pharmaceuticals Earns $5 Million Milestone Payment From Biogen Idec
7. CoLucid Pharmaceuticals Appoints Matthew Dallas as Chief Financial Officer and Treasurer
8. Valeant Pharmaceuticals To Announce 2014 Fourth Quarter And Full Year Results On February 24, 2015
9. Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen Idec for Advancing New Drug Into Development to Treat a Neurodegenerative Disease
10. Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients
11. Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study
Post Your Comments:
(Date:2/15/2020)... and FT. LAUDERDALE, Fla. (PRWEB) , ... February 14, 2020 , ... ... area, has joined the esteemed Haute Beauty Network. , The Haute Beauty Network, well ... Dr. Ray Lopez as a foot and ankle and our newest addition to the ...
(Date:2/15/2020)... ... , ... The creators of Dullo Plus - a premium cotton pillow ... to announce the launch of a Kickstarter campaign for 35 days starting, February 11, ... the last four years. Dullo Plus is their most advanced pillow to date , ...
(Date:2/14/2020)... , ... February 14, 2020 , ... ... medical services (EMS), fire departments and hospitals, today announced Dr. Daniel Kraft – ... of Exponential Medicine – will deliver one of three keynote presentations at ...
Breaking Medicine Technology:
(Date:2/19/2020)... , ... February 19, 2020 , ... ... Advanced Periodontics and Dental Implant Center of Connecticut, celebrate 30 years of serving ... with the same low fees that they charged in 1989, only thirty dollars. ...
(Date:2/19/2020)... ... 19, 2020 , ... MedTech IGNITE Expands Steering Committee, Faculty ... in 2020 Cohort , The Massachusetts Medical Device Industry Council ( MassMEDIC ) ... from startup founders and CEOs to participate in the 2020 IGNITE Cohort. ...
(Date:2/19/2020)... ... February 19, 2020 , ... Nvision Biomedical Technologies , ... portfolio for lower extremities at the American College of Foot and Ankle Surgeons ... Trigon® Ti Stand-Alone Osteotomy Wedge Fixation System will lead Nvision's innovative showcase. The ...
(Date:2/16/2020)... ... February 16, 2020 , ... Accumen Inc., the leader in ... and The Joint Commission to provide a complimentary series of Patient Blood Management ... and transfusion safety officers) within U.S. hospitals. , “Accumen’s mission is ...
(Date:2/15/2020)... ... February 14, 2020 , ... Sister companies, Special Learning ... “BIG MONEY IN ABA”. The series explores the challenges, risks, and opportunities of ... the series on March 25, 2020 at: , Since 2010, ...
Breaking Medicine News(10 mins):